Results 1 to 10 of about 103,375 (340)

Treatment of Aspergillosis [PDF]

open access: yesJournal of Fungi, 2018
Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis (IA) in those patients most at risk for infection, breakthrough IA does occur and remains difficult to diagnose due to low sensitivities of mycological tests ...
Jeffrey D. Jenks, Martin Hoenigl
openaire   +9 more sources

Invasive pulmonary aspergillosis in critically ill patients with pneumonia due to COVID-19, influenza, and communityacquired pneumonia: A prospective observational study [PDF]

open access: yesCurrent Medical Mycology, 2022
Background and Purpose: Influenza A and SARS-CoV-2 are risk factors for invasive pulmonary aspergillosis. Both influenza-associated pulmonary aspergillosis and COVID-19-associated pulmonary aspergillosis result in high mortality and poor clinical ...
Ahsan Syed   +7 more
doaj   +1 more source

Therapeutic effects of Rheumatoid Arthritis on Aspergillosis development [PDF]

open access: yesReviews in Clinical Medicine, 2020
Aspergillosis is a common fungal infection with systemic characteristics, which is caused by various species of Aspergillus. The infection could develop in immunocompromised and immunocompetent patients under specific circumstances. Based on the clinical
Ali AL-Janabi
doaj   +1 more source

Immunotherapy of aspergillosis [PDF]

open access: yesClinical Microbiology and Infection, 2012
Management of invasive aspergillosis in high-risk patients remains challenging. There is an increasing demand for novel therapeutic strategies aimed at enhancing or restoring antifungal immunity in immunocompromised patients. In this regard, modulation of specific innate immune functions and vaccination are promising immunotherapeutic strategies ...
Cristina Cunha   +4 more
openaire   +4 more sources

Invasive sinus aspergillosis with mycotic aneurysm of the vertebral artery and subarachnoid hemorrhage – Case report

open access: yesRadiology Case Reports, 2021
Invasive sinus aspergillosis is a rare life-threatening condition usually found in immunocompromised patients. The fungus spreads from paranasal sinuses into the central nervous system by direct extension or through blood vessels. Perineural spread is an
Maruša Mencinger, MD   +2 more
doaj   +1 more source

Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy

open access: yesClinical Infection in Practice, 2020
Objectives: We aimed to identify the frequency and risk factors for disease relapse following cessation of antifungal therapy in CPA. Methods: This retrospective audit at the National Aspergillosis Centre, Manchester, UK assessed outcomes for patients ...
Felix Bongomin   +5 more
doaj   +1 more source

Pleuropulmonary aspergillosis in an immunocompetent patient presenting as pleural-based peripheral lung mass: A sporadic occurrence

open access: yesJournal of Association of Pulmonologist of Tamil Nadu, 2021
The importance of knowledge about pulmonary aspergillosis has increased immensely in the era of COVID-19 as a significant number of post-COVID patients develop lung infection with aspergillosis, an entity called COVID-associated pulmonary aspergillosis ...
P Amal Johnson   +2 more
doaj   +1 more source

Invasive aspergillosis [PDF]

open access: yesMedical Mycology, 2000
Item does not contain ...
Verweij, P.E.   +6 more
openaire   +2 more sources

Late-onset isavuconazole-induced liver injury

open access: yesMedical Mycology Case Reports, 2018
Antifungal agents account for approximately 3% of Drug-Induced Liver Injury (DILI) cases. Isavuconazole is a novel triazole, and experience with long-term use of it is lacking.
Felix Bongomin   +4 more
doaj   +1 more source

Successful long-term terbinafine therapy in an asthmatic patient with Aspergillus sensitization and bronchiectasis

open access: yesMedical Mycology Case Reports, 2017
Severe asthma with fungal sensitization (SAFS) is estimated to affect ~25% of patients with poorly controlled asthma. Tri-azole therapy is effective in only 60–80% and side effects are common.
Isabel Rodriguez-Goncer   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy